As of December 31, 2024, Opus had cash and cash equivalents of $30.3 million. Based on current projections, management believes that the cash on hand will be sufficient to fund operations into the second half of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics presents data on phentolamine ophthalmic solution 0.75%
- Opus Genetics prices 21.05M shares at 95c in public offering
- Opus Genetics announces presentations at ARVO 2025 meeting
- Opus Genetics gets Fast Track designation for phentolamine ophthalmic solution
- Opus Genetics provides update on OPGx-LCA5 clinical program